HKSE:02186 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:02186 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Luye Pharma Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$13,706 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.
Total Stockholders Equity is used to calculate Book Value per Share. Luye Pharma Group's Book Value per Share for the quarter that ended in Dec. 2023 was HK$3.64. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Luye Pharma Group's Debt-to-Equity for the quarter that ended in Dec. 2023 was 0.67.
The historical data trend for Luye Pharma Group's Total Stockholders Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Luye Pharma Group Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Total Stockholders Equity | Get a 7-Day Free Trial | 9,914.98 | 9,354.52 | 10,393.43 | 11,363.64 | 13,706.35 |
Luye Pharma Group Semi-Annual Data | ||||||||||||||||||||
Jun14 | Dec14 | Jun15 | Dec15 | Jun16 | Dec16 | Jun17 | Dec17 | Jun18 | Dec18 | Jun19 | Dec19 | Jun20 | Dec20 | Jun21 | Dec21 | Jun22 | Dec22 | Jun23 | Dec23 | |
Total Stockholders Equity | Get a 7-Day Free Trial | 10,393.43 | 10,331.42 | 11,363.64 | 12,397.79 | 13,706.35 |
Luye Pharma Group (HKSE:02186) Total Stockholders Equity Explanation
1. Total Stockholders Equity is used to calculate Book Value per Share.
Luye Pharma Group's Book Value per Share for the quarter that ended in Dec. 2023 is
Book Value per Share | = | (Total Stockholders Equity | - | Preferred Stock) | / | Shares Outstanding (EOP) |
= | (13706.346 | - | 0) | / | 3761.67 | |
= | 3.64 |
2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.
Luye Pharma Group's Debt-to-Equity for the quarter that ended in Dec. 2023 is
Debt-to-Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (5683.006 | + | 3530.929) | / | 13706.346 | |
= | 0.67 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Luye Pharma Group's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Ubs Group Ag | 2201 Interest of corporation controlled by you | |
Liu Dianbo | 2301 Trustee | |
Luye Life Sciences Group Ltd | 2201 Interest of corporation controlled by you | |
Luye Pharma Holdings Ltd. | 2201 Interest of corporation controlled by you | |
Nelumbo Investments Limited | 2201 Interest of corporation controlled by you | |
Shorea Lbg | 2201 Interest of corporation controlled by you | |
Luye Pharmaceutical Investment Co., Ltd. | 2101 Beneficial owner | |
Ginkgo (ptc) Limited | 2301 Trustee | |
Luye Pharmaceutical International Co., Ltd. | 2201 Interest of corporation controlled by you | |
Yi Fang Da Ji Jin Guan Li You Xian Gong Si | 2102 Investment manager | |
Hillhouse Nev Holdings Limited | 2101 Beneficial owner | |
Hillhouse Investment Management, Ltd. | 2102 Investment manager | |
Hillhouse Fund V, L.p. | 2201 Interest of corporation controlled by you | |
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si | ||
Yang Yu Fen |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.